Advanced tobacco Products, Inc., d/b/a Advanced Therapeutic Products, Inc. was engaged in the manufacturing and marketing of a product based on nicotine technology. In 1987, ATP sold patented nicotine technology, know how and related assets to Pharmacia Corporation, a worldwide pharmaceutical company that manufactures the Nicotrol/Nicorette Inhaler (Inhaler), Nicorette Chewing Gum, the Nicotrol/Nicorette Patch, and the Nicotrol/Nicorette Nasal Spray. The nicotine technology acquired from ATP forms the basis of the Inhaler developed by PHA for use in the nicotine replacement therapy market. The Inhaler is the only nicotine replacement product designed to help control a smoker's cravings for cigarettes while providing a key behavioral component of smoking--the hand-to-mouth ritual. ATP receives product payments from sales of the Inhaler by PHA equal to 3% of PHA's net sales. In addition, ATP has an agreement with PHA under which, among other matters, ATP has the right to receive a royalty equal to 0.1 percent of net revenues received by PHA from the sale of any product using a nicotine impermeable copolymer technology. ATP also has an exclusive worldwide license to certain dry powder nicotine inhaler technology from Duke University. ATP has obtained several patents covering this technology. As of September 24, 2003, Advanced tobacco Products, Inc. operates as a subsidiary of IVAX Corp.
Advanced Tobacco Products: Private Company Information - BusinessWeek
Advanced Tobacco Products: Private Company Information - BusinessWeek